Close

Serbia gets shipment of AstraZeneca COVID-19 vaccine made in India

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Boehringer Ingelheim Integrates Owkin K Pro AI to Accelerate Drug Discovery

Boehringer Ingelheim has joined other pharmaceutical leaders in deploying Owkin's agentic AI scientist, K Pro, to analyze multimodal patient data in oncology and immunology R&D.
- Advertisement -

A shipment of 150,000 COVID-19 vaccines developed by AstraZeneca and Oxford University arrived at Belgrade airport on Sunday, making Serbia the first country in the Western Balkan region to receive supplies of the shot.

The vaccines, which arrived on a Turkish Airlines plane from Istanbul, were produced in India, said President Aleksandar Vucic, who came to the airport to meet the shipment.

Vucic said the price of the vaccine was “very good as both AstraZeneca and Oxford gave up their profits”. He added that another shipment of 150,000 vaccines is expected in 12 weeks time.

“This vaccine was developed by a young team at the Oxford University which also included young people from Serbia,” British ambassador Sian MacLeod told reporters at the airport.

More than 730,000 people, or a little over 10 per cent of the population, have been vaccinated against COVID-19 since December with one or two doses of the vaccines available in Serbia.

Under the state vaccination programme, Serbians have been able to choose between shots from Pfizer-BioNTech , China’s Sinopharm or Russia’s Sputnik V.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Boehringer Ingelheim Integrates Owkin K Pro AI to Accelerate Drug Discovery

Boehringer Ingelheim has joined other pharmaceutical leaders in deploying Owkin's agentic AI scientist, K Pro, to analyze multimodal patient data in oncology and immunology R&D.

EMA Initiates Data Sharing Pilot for New Approach Methodologies

The European Medicines Agency has launched a voluntary framework for sharing data from non-animal testing methods to build regulatory confidence and refine drug development.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »